Evidence map›Paper›PMID 40119730›Full record

ArticleNucleic acids research2025

A sequence-specific RNA acetylation catalyst.

Supuni Thalalla Gamage, Shereen Howpay Manage, Aldema Sas-Chen, Ronit Nir, Brett W Burkhart, Isita Jhulki, Courtney N Link, Manini S Penikalapati, Jane E Jones, Lakshminarayan M Iyer and 4 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Seven wonders of RNA modification biology.RNA (New York, N.Y.) · 2026
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Supuni Thalalla GamageChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.ORCID 0000-0002-1045-6306
Shereen Howpay ManageChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.
Aldema Sas-ChenThe Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, 6195001 Tel Aviv, Israel.
Ronit NirDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 7630031, Israel.
Brett W BurkhartDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, United States.
Isita JhulkiChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.
Courtney N LinkChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.
Manini S PenikalapatiChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.
Jane E JonesProtein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, United States.
Lakshminarayan M IyerComputational Biology Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, United States.
L AravindComputational Biology Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, United States.ORCID 0000-0003-0771-253X
Thomas J SantangeloDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, United States.ORCID 0000-0003-4559-3244
Schraga SchwartzDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 7630031, Israel.ORCID 0000-0002-3671-9709
Jordan L MeierChemical Biology Laboratory, National Cancer Institute, Frederick, MD 21702, United States.ORCID 0000-0002-0537-7101

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3M
Azrieli FoundationCCR NIH HHS ZIA BC011488European Research Council 101000970Intramural NIH HHS ZIA BC011488Israel Science Foundation 1260/23Israel Science Foundation 913/21National Science Foundation 2022065NCI NIH HHS 75N91019D00024NIH HHSNLM NIH HHS
6 · The paper itself

Abstract

N4-acetylcytidine (ac4C) is a ubiquitous RNA modification incorporated by cytidine acetyltransferase enzymes. Here, we report the biochemical characterization of Thermococcus kodakarensis Nat10 (TkNat10), an RNA acetyltransferase involved in archaeal thermotolerance. We demonstrate that TkNat10's catalytic activity is critical for T. kodakarensis fitness at elevated temperatures. Unlike eukaryotic homologs, TkNat10 exhibits robust stand-alone activity, modifying diverse RNA substrates in a temperature, ATP, and acetyl-CoA-dependent manner. Transcriptome-wide analysis reveals TkNat10 preferentially modifies unstructured RNAs containing a 5'-CCG-3' consensus sequence. Using a high-throughput mutagenesis approach, we define sequence and structural determinants of TkNat10 substrate recognition. We find TkNat10 can be engineered to facilitate use of propionyl-CoA, providing insight into its cofactor specificity. Finally, we demonstrate TkNat10's utility for site-specific acetylation of RNA oligonucleotides, enabling analysis of ac4C-dependent RNA-protein interactions. Our findings establish a framework for understanding archaeal RNA acetylation and a new tool for studying the functional consequences of ac4C in diverse RNA contexts.

Indexed as

AcetyltransferasesArchaeal ProteinsCytidineRNARNA, ArchaealThermococcusAcetylationAcetyl Coenzyme ASubstrate SpecificityAcetyl Coenzyme AAcetyltransferasesArchaeal ProteinsCytidineN-acetylcytidineRNARNA, Archaeal

Identifiers

PMID40119730
PMCPMC11928934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.